Monash University researchers have just launched Australia’s first clinical trial to test whether the psychedelic drug psilocybin is an effective treatment for persisting post-concussion symptoms.
There are few effective therapies for the debilitating long-term effects of mild traumatic brain injury, more commonly known as concussion.
But researchers now think psilocybin, a psychedelic compound found in some mushrooms, could be the answer.
Recent studies from Monash University indicate that a single macro-dose of the drug can reduce the symptoms that often show up after brain injury.
The project will leverage leading-edge capability and track record in neuro-imaging and biomarkers of psychedelics within the Monash Trauma Group, and clinical implementation and assessment within the Clinical Psychedelic Lab.
Lead researcher on the trial, Professor Terence O’Brien, Head of Monash University’s School of Translational Medicine, Program Director Alfred Brain, and Deputy Director of Research at Bayside Health Alfred, said the clinical trial is a huge step forward and will provide hope to many patients.
“Given the lack of effective treatment options for persisting and debilitating concussion symptoms, we are excited to be studying a promising new approach,” Professor O’Brien said.
“In addition to alleviating symptoms, research suggests it can also target the biological effects concussion has on the brain.”
https://www.miragenews.com/monash-launches-trial-on-psychedelic-therapy-1691985/#google_vignette
